Seasoned Ultrasound Expert to Guide Development Advances
Delphinus Medical Technologies, Inc., the first company to design and manufacture a whole breast ultrasound system that incorporates circular transducer technology, announced today that Chris Sanders has joined the executive team as vice president of engineering. He comes to Delphinus with over 20 years of extensive global innovation and manufacturing expertise in the medical ultrasound domain.
Prior to Delphinus, Sanders was Director of Ultrasound Research and Development at Toshiba Medical Research Institute, USA, where he led the global research group that drove the advancement of matrix array transducer design. With his direction the team established collaborative partnerships with renowned research institutions and generated multiple publications and strategic medical patents. During his 17 year career at Siemens Medical Solutions Corporation, he held numerous senior management positions. Recognized for attracting expert talent and leading international development teams to exceed corporate objectives, while Senior Director of Product Management, he steered the global launch and commercialization of several new product lines, leveraging multi-dimensional cross-platform synergies that streamlined the time-to-market process and increased margins substantially.
“Chris is a superb addition to the Delphinus team,” said Mark J. Forchette, recently appointed president and chief executive of Delphinus. “He brings a great depth of expertise and knowledge realized by the accomplishments he achieved during his tenure with leading medical imaging corporations. We look forward to his guidance and vision directing our research and development teams, as we advance our SoftVue technology to address the need for innovative solutions in breast cancer screening.”
Sanders earned his baccalaureate degree in mathematics from the University of Colorado, Boulder Colo., with an emphasis in computer science. He also holds a Management of Technology Certification from the Weatherhead School of Management at Case Western Reserve, Cleveland.
Delphinus is the first to introduce an automated whole breast ultrasound system that utilizes a ring transducer technology to transmit and receive ultrasound signals. SoftVue captures reflection echoes from all directions around the breast and gathers transmitted signals coming through the breast, something no other ultrasound system, currently available, can do. With a short scan time of one to two minutes per breast, SoftVue presents a volumetric image map of the whole breast, providing a consistent and uniform exam without reliance on operator skill and technique.
About Delphinus Medical Technologies, Inc.
Delphinus Medical Technologies, Inc. is a pioneering medical imaging company that has developed SoftVue™, the first circular array transducer technology that has received U.S. Food and Drug Administration clearance. The patented technology is a whole breast ultrasound tomography imaging device that delivers no radiation, requires no compression, and images the entire breast with a single scan. SoftVue is indicated for use as a B-mode ultrasonic imaging system and is not intended to be used as a replacement for screening mammography. Delphinus is capitalized through principal investments by Arboretum Ventures, Ann Arbor, Mich., Beringea, Farmington Hills, Mich., and North Coast Technology Investors, Ann Arbor, Mich. For more information, visit www.delphinusmt.com.
VP, Marketing and Sales
Delphinus Medical Technologies, Inc.